Ultralife (ULBI) Expected to Announce Quarterly Earnings on Monday

Ultralife (NASDAQ:ULBI) is anticipated to announce its Q4 2025 results before the market opens on Monday, February 23rd. Analysts expect Ultralife to post earnings of $0.24 per share and revenue of $57.00 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 26, 2026 at 7:00 AM ET.

Ultralife (NASDAQ:ULBI) last announced its earnings results on Monday, November 17th. The technology company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.21 by ($0.28). Ultralife had a net margin of 0.92% and a return on equity of 1.66%. The company had revenue of $43.37 million for the quarter, compared to the consensus estimate of $53.00 million.

Ultralife Price Performance

ULBI stock opened at $5.86 on Friday. The firm has a 50 day simple moving average of $6.15 and a two-hundred day simple moving average of $6.43. The stock has a market cap of $97.57 million, a PE ratio of 58.60 and a beta of 0.88. Ultralife has a one year low of $4.07 and a one year high of $9.52. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.99 and a quick ratio of 1.42.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d+)” rating on shares of Ultralife in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Insider Buying and Selling at Ultralife

In other Ultralife news, Director Bradford T. Whitmore acquired 28,588 shares of the business’s stock in a transaction dated Tuesday, December 16th. The stock was bought at an average price of $5.70 per share, with a total value of $162,951.60. Following the purchase, the director owned 1,235,631 shares of the company’s stock, valued at approximately $7,043,096.70. This trade represents a 2.37% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In the last three months, insiders have purchased 54,750 shares of company stock valued at $310,760. Insiders own 40.00% of the company’s stock.

Institutional Trading of Ultralife

Several hedge funds have recently added to or reduced their stakes in the business. Lazard Asset Management LLC boosted its position in Ultralife by 1,650.0% during the second quarter. Lazard Asset Management LLC now owns 5,565 shares of the technology company’s stock valued at $49,000 after buying an additional 5,247 shares during the period. Empowered Funds LLC bought a new stake in shares of Ultralife in the 4th quarter valued at about $44,000. Prelude Capital Management LLC purchased a new stake in Ultralife during the 3rd quarter valued at about $71,000. Bank of America Corp DE boosted its stake in shares of Ultralife by 30.7% during the fourth quarter. Bank of America Corp DE now owns 12,067 shares of the technology company’s stock valued at $90,000 after purchasing an additional 2,836 shares during the period. Finally, Jane Street Group LLC purchased a new stake in Ultralife during the 4th quarter valued at $75,000. 30.68% of the stock is owned by institutional investors.

About Ultralife

Ultralife Corporation (NASDAQ: ULBI) develops, manufactures and sells a broad range of energy and communications products for defense, medical, automotive and consumer electronics markets. The company operates through two primary segments: Power Systems and Communications Systems. In its Power Systems segment, Ultralife produces lithium-ion rechargeable cells and battery packs, primary lithium batteries, alkaline and rechargeable battery packs, chargers and battery accessories designed to meet demanding performance and safety requirements.